Carbamazepine for acute psychosis with EEG abnormalities.
OBJECTIVE
To investigate the efficacy of carbamazepine as adjuvant drug therapy in acute paranoid psychosis with associated EEG abnormalities, compared to sole antipsychotic treatment.


METHODS
Eleven medication-naive patients, diagnosed with acute paranoid psychosis with associated EEG abnormalities, were divided into two treatment groups: sole fluphenazine group, with flexible dosing of 5-10 mg/day (n=6), and carbamazepine group (n=5) with the addition of carbamazepine (600 mg/day) to fluphenazine treatment. Clinical Global Impression (CGI), Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), and EEG were assessed on the baseline and after 6 weeks of treatment. Paired and two-tailed t-tests were used for statistical significance.


RESULTS
All the patients showed significant improvement of mental state after 6 weeks of treatment with no significant differences in CGI, BPRS, and total SANS scores in relation to the therapy with carbamazepine. Nevertheless, after 6 weeks of the treatment, EEG findings were significantly better in carbamazepine group, in relation to the findings from the onset of the treatment, as well as in comparison to sole fluphenazine group.


CONCLUSIONS
Although carbamazepine stabilized abnormal brain electrical activities it seemed that the associated EEG abnormalities were not significant for acute psychosis observed. These preliminary results suggested that there was no convincing evidence that carbamazepine was efficient as the augmentation of antipsychotic treatment for patients with both acute paranoid psychosis and EEG abnormalities.
Ivković
Maja
M
Clinical Center of Serbia, Institute for Psychiatry, Belgrade, Serbia and Montenegro. majaivk@Eunet.yu
Damjanović
Aleksandar
A
Marinković
Dragan
D
Paunović
Vladimir R
VR
D000208:Acute Disease; D000328:Adult; D018692:Antimanic Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D002220:Carbamazepine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005476:Fluphenazine / Q000008:administration & dosage*; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy*
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D002220:Carbamazepine; D005476:Fluphenazine